Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication

After completion of a 6‐week double‐blind trial of asenapine sublingual tablets (10 or 20 mg/day) versus placebo in Asian patients with acute exacerbation of schizophrenia, including Japanese patients, this open‐label study evaluated the safety and efficacy of a 52‐week treatment with asenapine at f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Toshihiko, Takekita, Yoshiteru, Hiraoka, Shuichi, Tamura, Fumihiro, Iwama, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496045/
https://www.ncbi.nlm.nih.gov/pubmed/37232002
http://dx.doi.org/10.1002/npr2.12342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496045/
https://www.ncbi.nlm.nih.gov/pubmed/37232002
http://dx.doi.org/10.1002/npr2.12342

Ejemplares similares